Cathy has undertaken due diligence for many clients, including investors, academics, SMEs and government agencies in the UK and overseas. Services include undertaking due diligence to support an investment or licensing opportunity for a biotechnology-based product or service. Due diligence may include an assessment of the data package required to trigger a key decision, clarification of the unique selling proposition, competitive market positioning, the commercial strategy and business planning.
Cathy has also worked with and built-up a network of contacts with the re/insurance industry: on behalf of a third party and working closely with a leading global insurance broker, she has been intimately involved in the claims risk analysis and pricing structure for an innovate insurance product successfully underwritten by Lloyds of London. Cathy also established the ‘Quartet Consortium’ that brought together senior members of the leading global reinsurance industry to evaluate the potential impact of regenerative medicines on the protection industry.
Cathy is a Non-Executive Director to Videregen Ltd, a member of the TrakCel Ltd Advisory Board, member of the Worcester Polytechnic Institute (USA) Life Sciences Advisory Board, mentor to the Ignite Summer Business School programme (Centre for Entrepreneurial Learning, Cambridge University), Senior Associate for the Masters in Bioscience (Cambridge University) and Visiting Professor at Kings College, London. She has authored multiple peer-reviewed publications and is co-editor of the book ‘The Delivery of Regenerative Medicines and Impact on Healthcare’ (CRC Press).
